Lyell Immunopharma, Inc. (LYEL)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Lyell Immunopharma, Inc. reported revenue of $36.0K, down 41.0% from the prior year. The company ran a net loss, with a net margin of -762355.6%. It held $340.05M in total assets against $91.85M in total liabilities.
Key ratios (FY2025)
-748344.4%
Operating margin
-762355.6%
Net margin
-110.6%
Return on equity
-41.0%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $36.0K | $61.0K | $130.0K | $84.68M | $10.65M | $7.76M | $657.0K | — |
| Operating Income | -$269.40M | -$358.75M | -$247.01M | -$187.06M | -$214.78M | -$211.94M | -$102.09M | — |
| Net Income | -$274.45M | -$342.99M | -$234.63M | -$183.12M | -$250.22M | -$204.47M | -$129.38M | — |
| EPS (Diluted) | $-16.06 | $-26.23 | $-18.70 | $-0.74 | $-1.84 | $-15.69 | $-24.04 | — |
| Total Assets | $340.05M | $490.86M | $750.03M | $937.56M | $1.13B | $908.28M | — | — |
| Total Liabilities | $91.85M | $108.03M | $95.08M | $104.31M | $197.62M | $189.84M | — | — |
| Shareholders' Equity | $248.20M | $382.82M | $654.95M | $833.25M | $929.79M | -$292.53M | -$111.11M | $850.0K |
| Cash & Equivalents | $60.18M | $105.60M | $145.65M | $123.55M | $293.83M | $140.41M | $96.67M | — |
| Operating Cash Flow | -$150.02M | -$162.39M | -$163.69M | -$169.56M | -$126.25M | -$160.87M | $39.47M | — |
| Capital Expenditures | $780.0K | $464.0K | $2.69M | $24.28M | $65.50M | $51.48M | $16.05M | — |
| Shares Outstanding | 17.09M | 13.07M | 12.55M | 247.08M | 135.92M | 13.26M | 5.4K | — |